Care Fertility and U-Ploid Biotechnologies have announced an exciting collaboration aimed at enhancing egg quality and improving fertility treatment outcomes. This partnership seeks to tackle a major cause of infertility, which worsens significantly as women age.
The collaboration will combine Care Fertility’s clinical expertise and track record of high success rates with U-Ploid’s innovative biotechnological advancements. This joint effort has the potential to validate new treatments and bring hope to millions of people struggling to conceive.
Prof. Alison Campbell, Chief Scientific Officer at Care Fertility, expressed excitement about the partnership, saying, “We are thrilled to begin this collaborative research with U-Ploid Biotechnologies. Improving treatments for women facing age-related infertility is a key priority for us, and the possibility that this research could address the most common cause of infertility is remarkable.”
For U-Ploid Biotechnologies, this partnership is set to speed up the development of their leading therapeutic program, a pioneering treatment designed to tackle age-related egg deterioration. Dr. Jordan Abdi, Co-founder and CEO of U-Ploid, shared his enthusiasm: “We are excited to partner with Care Fertility as we take our next step in development. This collaboration gives us the opportunity to work closely with a respected leader in fertility care and gain valuable clinical insights.”
U-Ploid’s lead program has already shown promise in preclinical tests aimed at addressing the natural deterioration of eggs with age. The collaboration marks the beginning of a long-term research project, with plans to begin enrolling patients in the first study later this year.
Related Topics:
